FOSUN PHARMA
復星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
27 February 2025

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Jiangsu Xingsheng Xinhui Pharmaceutical Co., Ltd.* (江蘇星盛新輝醫藥有限公司) ("**Xingsheng Xinhui**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**"), recently received the approval from the National Medical Products Administration for the clinical trial of XS-03 tablets (registration category of applications: class 1 chemical medicine; "**XS-03**") in combination with FOLFOX or FOLFIRI and bevacizumab for the treatment of metastatic colorectal cancer with RAS mutations (hereinafter referred to as the "**Treatment Regimen**"). Xingsheng Xinhui intends to commence Phase Ib/II clinical trials of the Treatment Regimen in China (excluding Hong Kong, Macau and Taiwan, the same applies below) when the conditions are fulfilled.

II. Research Progress of the Drugs Involved in the Treatment Regimen

In this clinical study, XS-03 will be intended to be used for the treatment of metastatic colorectal cancer with RAS mutations in combination with FOLFOX or FOLFIRI and bevacizumab. Among them, FOLFOX or FOLFIRI combined with bevacizumab is currently the standard first-line treatment regimen for advanced metastatic colorectal cancer.

XS-03 involved in the Treatment Regimen is a small molecule oral PLK1 inhibitor developed by the Group (i.e., the Company and its holding subsidiaries/units, the same applies below). XS-03 mainly exerts its anti-tumor effects by inhibiting a cell cycle regulator, causing mitotic arrest and subsequent cell death. In addition, XS-03 has synthetic lethal effect with KRAS mutations，resulting in strong inhibitory effect on colorectal cancer cells harboring KRAS mutations. XS-03 has demonstrated significant anti-tumor efficacy in various preclinical tumor models, with a favorable safety profile observed in Phase 1 trial. As of the date of this announcement (i.e. 27 February 2025, the same applies below), XS-03 monotherapy for the treatment of advanced solid tumors with RAS mutations is in the stage of Phase I clinical trial in China.

As of January 2025, the Group had invested approximately RMB 200,000 (excluding single drugs, unaudited) in total in the research and development (the "**R&D**") of the Treatment Regimen at this stage.

As of the date of this announcement, no treatment regimen of small molecule inhibitor with the same target, either as monotherapy or in combination, has been approved for marketing worldwide.

III. Risk Reminder

As required by the relevant laws and regulations in China, the Treatment Regimen and the drug XS-03 involved is subject to undergo a series of clinical studies and approval by the relevant national drug review department in China before it can be launched. There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and launch of new drugs is a long-term task involving various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

27 February 2025